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Abstract, The number and affinity of glucocorticoid binding sites in peripheral mononuclear leukocytes of patients 
with atopic dermatitis (AD) and healthy controls were determined under baseline conditions and after a defined oral 
glucocorticoid treatment. Patients with A D (n = 15) exhibited significantly more glucocorticoid receptors (GR) per cell 
than the control group (n = 22), while the G R affinity did not differ. Methylprednisolone treatment resulted in a signif-
icant reduction of the G R sites per cell in the steroid-treated control group (n = 10) in contrast to the patients. The dis-
sociation constant was not affected by methylprednisolone treatment in either group. In view of the therapeutic effi-
ciency of glucocorticoids in A D and findings of abnormal c A M P and cAMP-phosphodiesterase activity, the elevated 
G R concentrations in A D lend support to the hypothesis of a compensatory G R upregulation due to an insufficient 
action of endogenous Cortisol or to altered cAMP-induced G R expression. 
Introduction 
Studies on patients with atopic dermatitis (AD) have 
revealed a variety of immunological, hormonal and psy-
chological [1,2] derangements including elevations of IgE 
levels [3, 4], disordered cell-mediated immunity [5-7], 
abnormal c A M P and cAMP-phosphodiesterase activity 
[8, 9] and an impairment of p-adrenoceptor function [10, 
11]. Recent investigations pointed to a possible hormonal 
dysregulation of the hypothalamic-pituitary-adrenal 
(HPA) system in A D . Slightly lowered baseline values of 
Cortisol [12] in face of a normal adrenomedullar function 
[13], minor imbalances in the circadian rhythm of Cortisol 
serum levels [14] as well as a reduced urine excretion rate 
of steroid metabolites contrasting with normal Cortisol 
blood levels [15] have been noted. 
Topical and systemic administration of glucocorticoids 
is of major importance in the treatment of A D . The 
effects of glucocorticoids are mainly mediated via specific 
intracellular receptors which have been identified in vari-
ous mammalian and human tissues, e.g. the skin [16-18], 
lung [19], brain [20] and mononuclear leukocytes [21-23]. 
As the glucocorticoid receptor (GR) has been shown 
to underlie an autoregulatory control in skin fibroblasts 
[17, 18] and in human leukocytes [21-26], the present 
study was designed to explore the potential role of G R 
autoregulation for the alteration of the H P A system in 
A D . 
Material and Methods 
Subjects 
Fifteen inpatients (3 men and 12 women) suffering from A D and 22 
healthy controls (11 men, 11 women) without personal history of asth-
ma, hay fever or A D participated in the study voluntari ly with informed 
consent. The patients were aged between 18 and 36 years ( m e a n ± S D : 
23.4 ± 5.6) and the controls for baseline studies between 19 and 42 years 
( m e a n ± S D : 28.5 ± 6 . 3 ) . Ten of the healthy subjects (4 men, 6 women; 
mean age ± S D : 24.3 ± 2.8 years), who had the same age as the patients, 
agreed to further participate in the study and received the same steroid 
dosage as the patients for the autoregulation study. 
A l l participants were withdrawn from any systemic therapy with 
corticoids or adrenocorticotropic hormone at least 2 months prior to the 
study. M e d i c a t i o n , if any, with (3-blocking and/or sleep-inducing drugs 
was stopped 3 or more days before entering the study. Cutaneous 
lesions of A D were treated only with corticoid-free ointments at least 
1 week before onset and during the study. 
Exc lus ion cri ter ia were prevalence of severe internal illness and 
alcohol, drug or nicotine abuse. Seven of the patients and 4 of the 10 
healthy controls were taking birth control pills. 
The diagnosis of A D was based on the history of recurrent flexura! 
eczema, personal and/or family history of atopy and clinical criteria of 
A D as established by Hani f in and Rajka [27]. The severity of cutaneous 
involvement was evaluated according to Costa ct a l . [28] and revealed 
moderate to marked disease activity. The score ranged between 37 and 
69points ( m e a n ± S D : 4 7 . 6 ± 10.6) before therapy and between 11 and 
55 points ( m e a n ± S D : 27.9+10.7) at the end of the study. None of the 
patients suffered from actual bronchial asthma. 
Study Design 
Af te r obtaining the baseline G R and hormone parameters, all 
patients and the steroid-treated controls underwent a 1-mg dcxametha-
sone suppression test ( D S T ) and subsequent oral methylprednisolone 
therapy as shown in table 1. The D S T was used to evaluate the integrity 
of the feedback regulation of the H P A system. 
F o r determinat ion of G R binding characteristics and hormone data 
peripheral venous b lood samples were collected into E D T A - c o n t a i n -
ing plastic tubes (Sarstedt, F R G ) . 
Cell Preparation and Binding Assay 
Mononuc lea r cel l fraction was prepared by sodium metrizoate-
F ico l l (Sigma, St. L o u i s , M o . , U S A ) density gradient cent! if ligation 
[29]. Ce l l s were washed twice in phosphate-buffered saline ( P B S , p i I 
7.4; Boehr inger , M a n n h e i m , F R G ) for 10 min , incubated for 60 min at 
37 °C in P B S and then washed again to allow sufficient dissociation of 
endogenous hormone. The final concentration of cells was determined 
using a Coul te r counter ( M o d e l S5, Coul ter Electronics L t d . U K ) . V i a -
bili ty of cells exceeded 9 5 % , as judged from their ability to exclude try-
pan blue. Contaminat ion by erythrocytes was < 10%, by granulocytes 
and monocytes < 8 % . 
B i n d i n g experiments as described by Rupprecht et al . [25] were 
carried out at 37 °C in plastic microti ter plates in a total volume of 0.25 
m l . The displacing compound in a final concentration of 10 \iM unla-
beled dexamethasone (Sigma, St. Lou i s , M o . . U S A ) solved in 5% ctha-
no l , containing 5 m M D-glucose, was added to half of the samples to 
determine nonspecific binding immediately prior to the addition of 
[ 3 H]dexamethasone ( A m e r s h a m , U K ) . Increasing concentrations of 
[ 3 H]dexamethasone (specific activity: 84 Ci /mmol) from 1 to 40 nA/ 
were used. Saturation experiments were carried out at equil ibrium 
after 90 min incubation in P B S with 5 vaM D-glucose at 37 C . After 
incubation, bound ligand was separated from free ligand by rapid filtra-
tion through Scatron filters ( N o . 11731) with a Titertek cell harvester 
by two 5-second washes with P B S at room temperature. The filters 
were transferred into plastic vials , 5 ml of a toluene-based scintillation 
cocktail was added (Rotiszint 22: Ro th . Karlsruhe. F R G ) and they 
were monitored for tri t ium in a Beckman L S 1801 counter at about 54% 
efficiency. A l l samples were assayed in triplicate with a variation coef-
ficient < 7 % . 
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F i g . 1. Seatehard plot of | \ I |dexamethasone binding to human 
mononuclear leukocytes. Specifically bound/free ( ( H|dexamethasone 
is plotted versus specifically hound f H )dexamethasone. 
Table 1. Study design 
Day Time C J1 ucoeoriicoid doses 
1 7 a.m. 
4 p .m. 
11 p.m. 1 mg dexamethasone 
2 7 a.m. 
4 p.m. 
3--6 7a .m. 8 mg methylprednisolone 
7 -S 7a .m. 4 mg methylprednisolone 
8 4p .m. 
Table 2. Cortisol mean 4 S D values ( 
controls (n 10) 
A B 
7 a ,m. 4 p . m . 7 a 
B lood samples 
hormone data 
hormone -f receptor data 
hormone data 
hormone data 
hormone -f receptor data 
C 
4 p . m . 4 p . m . 
Patients 27.5 + 13.8 13.4 + 11.3 1.6 + 1.4 4.1 + 4.0 5.6 ± h.9 
Controls 25.1 t 8.6 14.6 + 6.9 2.3 + 1.5 3.3 + 3.3 7.7 i 5.7 
A Baseline levels. K after oral administration of 1 mg dexame-
thasone: C after oral methylprednisolone treatment. 
Table 3. G R sites in female patients and female controls taking and 









n - 7 
3.783 + 1.658 
3.353 +. 1.105 
n - 4 
2.642 * 567 
2.030 + 470 
N o pill 
n - 5 
3.886+ 1.537 
3.250 ± 1.643 
n - 2 
2.764 + 85<> 
2.087+ 14 
5,000 -I 
Baseline Corticoid treatment 
F i g . 2. G R sites per ce l l . M e a n s ± S E , i n patients wi th A D ( • , 
n = 15), the cort icoid-treated controls ( H , n = 10) and the whole cont ro l 
group ( • , n = 22) before (baseline) and after g lucocor t icoid treatment. 
The asterisks indicate significant differences ( p < 0 . 0 2 ) . 
Baseline Corticoid treatment 
F i g . 3. K d . M e a n s ± S E , in patients wi th A D ( • . n = 15), the cor t i -
coid-treated controls ( ^ , n = 10) and the whole control group ( • , 
n —22) before (baseline) and after g lucocor t icoid treatment. 
Recep tor levels and the dissociat ion constant ( K d ) were de te rmined 
by Scatchard plots [30]. A typica l Scatchard plot of [ 3 H]dexamethasone 
is shown i n figure 1. 
Specif ic b ind ing was de termined by subtracting the nonspecific 
f rom total b ind ing . Nonspeci f ic b ind ing ( in percent o f total b inding) at a 
concentra t ion of 10 nM [ 3 H]dexamethasone was 28 ± 18% in patients 
and 26 ± 15% i n controls . 
Cortisol Assay 
C o r t i s o l was measured by an enzyme- l inked immunoassay ( E l i a s , 
F r e i b u r g , F R G ) . T h e lower detect ion l imi t was 22 nmol/1, and the in t ra-
and interassay coefficients of var ia t ion were 6% for both . 
C o r t i s o l nonsuppress ion was defined as the inabi l i ty to suppress 
both postdexamethasone Cortisol levels to below 5 ug/dl [31]. 
Statistical Analysis 
Pre l imina ry estimates o f b ind ing parameters f rom saturat ion 
experiments were p rov ided by the E B D A program. F i n a l estimates of 
b ind ing parameters were de te rmined wi th a compute r ized nonl inear , 
least-square regression analysis [32]. T h i s weighted curve fi t t ing pro-
gram assumes b ind ing according to the law of mass act ion to indepen-
dent classes o f b ind ing sites. T h e results are expressed as the mean 
± S D , and as the m e a n ± S E in the figures. 
D a t a were analyzed using the t-test for pa i red or group samples and 
Pearson's product moment cor re la t ion . A l l significance levels are two-
ta i led . 
Results 
Cortisol mean values of the patients and the controls 
did not differ significantly at any of the blood sampling 
time points during the 1-mg DST (table 2). Three of the 
patients and 2 of the controls fulfilled the criterion for Cor-
tisol nonsuppression. 
Comparison of the postmethylprednisolone Cortisol 
levels to the 4 p.m. baseline levels revealed significant 
reduction in patients and controls (p<0.03). 
The patients had significantly (p<0.02) more G R sites 
per cell than controls (fig. 2). After methylprednisolone 
therapy the patients revealed a slightly smaller mean 
number of G R sites per cell in relation to the baseline val-
ues (mean baseline: 3,894± 1,521; after treatment: 
3,394± 1,189, not significant), whereas in the controls 
(n= 10) a significant reduction of the G R sites was found 
(mean baseline: 2,695 ±582; after treatment: 2,036 ±410 , 
p<0.02). 
The significantly more G R binding sites per cell per-
sisted after therapy in the patient group when compared 
with the steroid-treated control group (p<0.002). 
There was no difference in baseline or methylpredniso-
lone-treated G R sites between female subjects taking 
birth control pills and those who did not (table 3). 
The K d did not differ at baseline condition and after 
methylprednisolone treatment in both groups (fig. 3). No 
relations were found between age, sex, Cortisol levels, 
severity of the skin disorder and G R binding parameters 
under the conditions studied. 
Discussion 
Although slightly lowered baseline Cortisol serum con-
centrations in patients with A D have been observed [12], 
our study is in accordance with reports on normal Cortisol 
levels in A D [15]. Twenty percent of the patients with A D 
and 20% of the controls showed no suppression of Cortisol 
to below 5 [xg/dl after 1 mg dexamethasone. However, 
abnormal DST data may not only occur in various dis-
eases but can also be induced by multiple interference fac-
tors such as stress and weight loss in healthy subjects [33, 
34]. Therefore, the abnormal DST results obtained in A D 
and healthy controls may represent an unspecific finding. 
As no data are available on G R binding characteristics 
in A D we used peripheral blood mononuclear leukocytes 
to study G R pharmacology, partly for their easy accessi-
bility but also for their relevance to the pathogenesis in 
A D [35] as emphasized by the finding that bone marrow 
transplantation for other reasons could either confer the 
state of atopy to former nonatopics [36, 37] or may clear 
A D in patients with a concomitant immune deficiency 
disorder [38]. 
The elevated G R concentrations found in the patients 
with A D are probably not representing a causal factor, 
otherwise worsening of the skin lesions would be expected 
at the beginning of glucocorticoid treatment due to an 
increased number of activated hormone-receptor com-
plexes. A n upregulation of the glucocorticoid binding 
sites as a compensatory mechanism is more likely. Possi-
ble hypotheses for such an upregulation may be altera-
tions in cAMP-induced G R expression [39], activation of 
the G R synthesis by unspecific mediators [40] or a relative 
biological inefficiency of endogenous corticoids. The lat-
ter hypothesis might be supported by the well-known ben-
efit of glucocorticoids for the treatment of A D and also by 
the frequent occurrence of a rebound phenomenon after 
discontinuation of glucocorticoid administration. A n 
increase in receptor protein half-life [39, 41] due to 
reduced cortisol-receptor interactions as supposed after 
depletion of endogenous Cortisol following metyrapone 
administration [26] or adrenalectomy [42], or an 
enhanced transcription rate for the G R [43] may also be 
responsible for the elevated G R sites in A D . 
No correlations were found between endogenous Cor-
tisol levels and G R binding sites in the control and patient 
group. This result is in accordance with previous studies in 
healthy and asthmatic subjects [26, 44, 45] and indicates 
that the plasma concentrations of endogenous glucocorti-
coids at the time of the G R assay are of minor importance 
for the estimation of G R number. 
However, prolonged glucocorticoid administration 
results in downregulation of the number of G R [18, 21, 
24] by influencing G R gene transcription [46] without sig-
nificantly affecting the binding affinity. In the controls 
methylprednisolone administration was followed by a sig-
nificant decrease in G R binding, whereas in the patients 
with A D only a slight reduction of G R binding was 
observed. This finding might be interpreted as a dimin-
ished downregulation of G R by exogenous glucocorti-
coids which could be due to the heterogeneity of the 
patient group shown by the greater standard deviation 
and might also be compatible with the hypothesis of a 
cAMP-induced overdrive of G R expression [39] or a rela-
tive biological inefficiency of endogenous Cortisol which 
would require a greater amount of exogenous glucocorti-
coids to downregulate the G R . However, it cannot be 
excluded that an eventual displacement of receptor-
bound methylprednisolone by dexamethasone during the 
assay may underlie different kinetics in patients with A D 
which might affect the estimation of K d and B m a x values. 
The use of monoclonal antibodies for quantification of 
G R expression [47] might overcome the difficulties with 
ligand exchange assays and furnish a direct proof for the 
hypothesis of a decreased G R downregulation in A D . 
As no data are available on G R in other inflammatory 
skin diseases so far, the specificity of the present findings 
is still questionable. However, although A D and bron-
chial asthma are often closely associated [48] and gluco-
corticoid therapy is efficient in both diseases [44], normal 
lymphocyte G R content and affinity has been described in 
asthmatic subjects [44, 45]. 
In line with observations that patients with A D exhibit 
a minor derangement of the H P A system shown by imbal-
ances of the circadian rhythm of Cortisol [14] and may have 
a reduced excretion of glucocorticoids [15], the here re-
ported alterations in G R binding characteristics on mono-
nuclear leukocytes lend further support to the view of A D 
as being a systemic rather than a mere cutaneous disease. 
Future perspectives might be the concomitant analysis 
of G R behavior in mononuclear leukocytes and cells of 
both involved and uninvolved skin areas of patients with 
A D . 
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